Monograph

C08CA06 - Nimodipine

Propably not porphyrinogenic

Rationale

Nimodipine is metabolized by CYP 3A4, but it is not observed or suspected that nimodipine has potential for induction or inhibition of any CYP-enzymes.

Chemical description

Dihydropyridine calcium antagonist.

Therapeutic characteristics

Nimodipine is indicated for the prevention of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage. It is administered orally or as an intravenous infusion.

Metabolism and pharmacokinetics

Nimodipine is metabolized by CYP 3A4. Effects on CYP enzymes by induction or inhibition have not been extensively studied. Formal interaction studies are also lacking but concomitant administration of oral nimodipine and diazepam, digoxin, glibenclamide, indometacin, ranitidine and warfarin did not reveal any potential for mutual interaction. (Liu 2000, SPC) No CYP-interactions with nimodipine as perpetrator are listed in commonly used drug- interaction databases (Lexi-Interact, Norwegian medicines agency, SuperCYP, the Danish Health and medicines authority). Nimodipine is not listed as a mechanism-based inhibitor or an inducer (Hisaka 2010, Isoherranen 2009, Pelkonen 2008).

Similar drugs

Explore alternative drugs in similar therapeutic classes C08C / C08CA or go back.

References

#	Citation details	PMID
*	Scientific articles
1.	Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Hisaka A, Ohno Y, et al. Pharmacol Ther. 2010 Feb;125(2):230-48.	19951720
2.	Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Isoherranen N, Hachad H, et al. Chem Res Toxicol. 2009 Feb;22(2):294-8.	19216580
3.	Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Liu XQ, Ren YL, Qian ZY, Wang GJ. Acta Pharmacol Sin. 2000;21:690–694.	11501176
4.	Inhibition and induction of human cytochrome P450 enzymes: current status. Pelkonen O, Turpeinen M, et al. Arch Toxicol. 2008 Oct;82(10):667-715.	18618097
5.	SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Preissner S, Kroll K, rt al. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43.	19934256
*	Government bodies
6.	Norwegian medicines agency. Find medicine.
*	Drug interaction databases
7.	Lexi-Interact, via UpToDate.
8.	The Danish Health and Medicines Authority. The drug interaction database.
*	Summary of Product Characteristics
9.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Nimotop.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames